Guidelines for diagnosing and managing babesiosis were published in November 2020 by the Infectious Diseases Society of America (IDSA).[1]
Diagnosis
The IDSA recommends peripheral blood smear examination or polymerase chain reaction (PCR) rather than antibody testing for diagnostic confirmation of acute babesiosis.
The IDSA recommends confirmation of a positive Babesia antibody test with blood smear or PCR before considering treatment.
Management
The IDSA recommends treating babesiosis with the combination of atovaquone plus azithromycin or the combination of clindamycin plus quinine.
The IDSA suggests exchange transfusion using red blood cells in selected patients with severe babesiosis.
The IDSA recommends monitoring Babesia parasitemia during treatment of acute illness in immunocompetent patients using peripheral blood smears. The IDSA recommends against testing for parasitemia once symptoms are resolved.
The IDSA suggests monitoring Babesia parasitemia in immunocompromised patients using peripheral blood smears even after patients become asymptomatic and until blood smears are negative. The ISDA suggests PCR testing be considered if blood smears become negative but symptoms persist.
For more Clinical Practice Guidelines, go to Guidelines.
For more information, go to Babesiosis.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Babesiosis Clinical Practice Guidelines (IDSA, 2020) - Medscape - Feb 01, 2021.
Comments